Pear Therapeutics, Inc.
PEAR · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $163,674 | $702,634 | $1,377,990 | $1,377,990 |
| - Cash | $48,301 | $169,567 | $110,900 | $27,415 |
| + Debt | $37,607 | $26,993 | $26,345 | $15,163 |
| Enterprise Value | $152,980 | $560,060 | $1,293,435 | $1,365,738 |
| Revenue | $12,694 | $4,208 | $9,384 | $32,562 |
| % Growth | 201.7% | -55.2% | -71.2% | – |
| Gross Profit | $4,512 | -$1,025 | $7,666 | $31,564 |
| % Margin | 35.5% | -24.4% | 81.7% | 96.9% |
| EBITDA | -$169,399 | -$152,425 | -$75,215 | -$51,704 |
| % Margin | -1,334.5% | -3,622.3% | -801.5% | -158.8% |
| Net Income | -$23,740 | -$20,294 | -$100,583 | $12,391 |
| % Margin | -187% | -482.3% | -1,071.9% | 38.1% |
| EPS Diluted | -0.17 | -0.18 | -0.73 | 0.09 |
| % Growth | 5.6% | 75.3% | -912% | – |
| Operating Cash Flow | -$113,895 | -$109,043 | -$67,894 | -$36,596 |
| Capital Expenditures | -$3,470 | -$4,628 | -$3,900 | -$281 |
| Free Cash Flow | -$117,365 | -$113,671 | -$71,794 | -$36,877 |